The International Society for Stem Cell Application (ISSCA) proudly announces the upcoming International Certification in Cellular Therapies Training, scheduled to be held in Seoul, Korea, from May 3rd to May 5th, 2024. Sponsored by Global Stem Cells Group, N-BIOTEK Group, Yonsei IMI Stem Clinic, and Regen IC, this training program stands as a pivotal event in the realm of regenerative medicine education.
Commencing on May 3rd with the theoretical component, the training will seamlessly transition into two days of immersive hands-on sessions on May 4th and May 5th at the Yonsei IMI Stem Clinic’s Stem Cell Center. Under the overarching theme of advancing regenerative medicine, the certification training will encompass a broad spectrum of topics, including bone marrow stem cell training and adipose-derived stem cell training, featuring live demonstration therapies and interactive practices. A notable feature of the event includes a Certificate of Completion Ceremony, acknowledging the accomplishments of participants.
Esteemed physicians and researchers will lead panel discussions, delving into the latest advancements in regenerative medicine. Key topics to be explored encompass molecular biology, treatment modalities in surgical and cosmetic applications, and groundbreaking technological innovations propelling the field forward.
A significant highlight of the certification training will be the unveiling of cutting-edge technologies in regenerative medicine and cellular therapies. Attendees will have the unique opportunity to witness live demonstrations of Cellgenic bone marrow kits, which have showcased remarkable efficacy in augmenting stem and progenitor cell concentrations in bone marrow aspiration compared to conventional needles. Overcoming limitations associated with traditional needles, such as restricted flow and impurities in aspirated marrow, these kits represent a monumental leap forward in the field.
Benito Novas, founder of Global Stem Cells Group and Head of Public Relations of ISSCA, expressed, “Through this training and hands-on demonstrations, we aim to further propel the field towards new frontiers of innovation and clinical application.”
Dr. Daeyong Kim, former President, stated, “I am pleased to host this training in Korea, facilitating opportunities for local physicians to advance their expertise in regenerative medicine, thus expanding access to its benefits for our community.”
Dr. Salih Yildirim, the new President, conveyed his enthusiasm, saying, “It is with great pleasure that I return to Korea. Presently, we are organizing several exceptional events, with Korea being a prominent destination among them. We anticipate announcing further initiatives in the near future.”
About ISSCA:
The International Society for Stem Cell Application (ISSCA) is a global network of regenerative medicine practitioners dedicated to advancing the field of stem cell therapy through education, research, and advocacy. With chapters spanning across the globe, ISSCA serves as a platform for collaboration and knowledge exchange among professionals in the regenerative medicine community.
About Global Stem Cells Group:
The Global Stem Cell Group is a family of several companies focused on stem cell medicine and research. The company uses its network to bring leadership in regenerative medicine training, research, and patient applications.
GSCG’s mission is to allow physicians to present the benefits of stem cell medicine to patients worldwide. The company also partners with policymakers, educators, and regulators to promote regenerative medicine.
Global Stem Cells Group is a publicly traded company operating under the symbol MSSV. https://finance.yahoo.com/quote/mssv/
To learn more about Global Stem Cells Group, Inc.’s companies visit our website www.stemcellsgroup.com or call +1 305 560 5331
Safe Harbor Statement:
Statements in this news release may be “forward-looking statements”. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions, or any other information relating to our future activities or other future events or conditions. These statements are based on current expectations, estimates, and projections about our business based partly on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties, and assumptions that are difficult to predict. Therefore, actual outcomes and results may and are likely to differ materially from what is expressed or forecasted in forward-looking statements due to numerous factors. Any forward-looking statements speak only as of the date of this news release, and The Global Stem Cells Group undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date of this news release. This press release does not constitute a public offer of any securities for sale. Any securities offered privately will not be or have not been registered under the Act and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.
